Neuland Laboratories Ltd
NSE:NEULANDLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neuland Laboratories Ltd
Cash Equivalents
Neuland Laboratories Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
Cash Equivalents
₹152.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash Equivalents
₹9.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash Equivalents
₹8B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash Equivalents
₹122.6B
|
CAGR 3-Years
32%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-1%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash Equivalents
₹30.4B
|
CAGR 3-Years
46%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash Equivalents
₹7.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Neuland Laboratories Ltd
Glance View
Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.
See Also
What is Neuland Laboratories Ltd's Cash Equivalents?
Cash Equivalents
152.2m
INR
Based on the financial report for Dec 31, 2025, Neuland Laboratories Ltd's Cash Equivalents amounts to 152.2m INR.
What is Neuland Laboratories Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-12%
Over the last year, the Cash Equivalents growth was 5%. The average annual Cash Equivalents growth rates for Neuland Laboratories Ltd have been 4% over the past three years , -12% over the past five years .